Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: December 4, 2025
Principal Executive Offices: Amsterdam, The Netherlands
Trading Symbol: QURE (Nasdaq Global Select Market)
This filing discloses a significant regulatory update regarding the Company's investigational gene therapy, AMT-130, for the treatment of Huntington's disease.
Key Financial Metrics
This Form 8-K is a current report regarding a specific event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. Investors should refer to the Company's most recent Form 10-Q (filed November 10, 2025) or Form 10-K (filed February 27, 2025) for financial metrics.
Material Changes and Regulatory Update
- Event: Receipt of final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a pre-Biologics License Application (BLA) meeting held on October 29, 2025.
- FDA Feedback: The FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission.
- Company Response: uniQure is evaluating the feedback and plans to urgently request a follow-up meeting with the FDA in the first quarter of 2026.
Outlook, Risks, and Management Commentary
Forward-Looking Statements: The filing contains forward-looking statements regarding the timing and outcome of future regulatory interactions and the potential need for additional clinical development.
Key Risks Identified:
- Phase I/II trials may fail to demonstrate data sufficient for further development or regulatory approval.
- The FDA may conclude current trials are not adequate and well-controlled to support a BLA.
- Uncertainty regarding whether the Company can conduct and fund a Phase III or confirmatory study if required.
- Risks related to the Company's ability to raise additional capital on acceptable terms to fund operations.
- Potential for new patient data to alter the interpretation of topline data.
Investor Verification Checklist
- Verify the specific content of the press release furnished as Exhibit 99.1 for detailed clinical context.
- Review the Company's most recent Form 10-Q (November 10, 2025) to assess current cash runway and liquidity given the potential need for additional funding.
- Monitor the Company's announcement regarding the scheduling of the follow-up FDA meeting in Q1 2026.
- Assess the impact of the FDA's feedback on the probability of AMT-130 achieving regulatory approval without a Phase III trial.